TriSalus Life Sciences (TLSI) announced changes to its Board of Directors. TriSalus announced that Dr. Arjun Desai, a member of the Board since August of 2023, has elected to resign from the Board. Concurrently, TriSalus announced that Michael Stansky has been appointed to the Company’s Board of Directors, effective February 4, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus Life Sciences sees FY26 revenue $60M-$62M, consensus $63.77M
- TriSalus Life Sciences reports preliminary Q4 revenue $13.2M, consensus $12.68M
- TriSalus Life Sciences named a 2026 Top Pick at Northland
- Expanding Indications and Diversified Revenue Base Support Buy Rating on TriSalus Life Sciences
- TriSalus Life Sciences price target raised to $12 from $11 at Canaccord